Profile photo Rene Bernards

Rene Bernards

Full Professor

Strategic program(s):


Rene Bernards has been a staff scientist at the Netherlands Cancer Institute since 1992 and was appointed part time professor of molecular carcinogenesis at Utrecht University in 1994. His scientific accomplishments include the development of MammaPrint, the first clinically-used gene expression profile for breast cancer. To bring this discovery to the clinic he co-founded “Agendia”, a genomics-based diagnostic company that started offering the first microarray-based diagnostic test for the clinical management of breast cancer in 2004. His laboratory also developed the first shRNA vector for gene silencing in mammalian cells and used this vector to create the first genome-scale library of shRNA vectors. His laboratory has used this vector collection to identify biomarkers of response to cancer drugs and to identify particularly powerful drug combinations for the treatment of cancer, based on the concept of synthetic lethality. There are currently several clinical trials that test the efficacy of combination therapies suggested by his genetic screens.

Strategic program(s):


Recent publications

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer Robin M J M van Geel, Emilie M J van Brummelen, Ferry A L M Eskens, Sanne C F A Huijberts, Filip Y F L de Vos, Martijn P J K Lolkema, Lot A Devriese, Frans L Opdam, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D R Huitema, Jos H Beijnen, René Bernards, Jan H M Schellens
British Journal of Cancer, 2020, vol. 122, p.1166-1174
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer Sanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, Frans L Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D R Huitema, Jos H Beijnen, René Bernards, Jan H M Schellens
Cancer Chemotherapy and Pharmacology, 2020, vol. 85, p.917-930
POSEIDON trial phase 1B results Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen, Meiling Gao, Mariette Schrier, Ingrid A.M. Mandjes, Javier Garcia-Corbacho, Anne Laure Vallier, Greig Dougall, Erik van Werkhoven, Constanza Linossi, Sanjeev Kumar, Harm van Tinteren, Maurizio Callari, Emma Beddowes, Jose Manuel Perez-Garcia, Hilde Rosing, Else Platte, Petra Nederlof, Margaret Schot, Aurelia de Vries Schultink, Rene Bernards, Cristina Saura, William Gallagher, Javier Cortes, Carlos Caldas, Sabine C. Linn
Clinical Cancer Research, 2019, vol. 25, p.6598-6605
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells Anna Ressa, Evert Bosdriesz, Joep de Ligt, Sara Mainardi, Gianluca Maddalo, Anirudh Prahallad, Myrthe Jager, Lisanne de la Fonteijne, Martin Fitzpatrick, Stijn Groten, A. F. Maarten Altelaar, Rene Bernards, Edwin Cuppen, Lodewyk Wessels, Albert J. R. Heck
Molecular & Cellular Proteomics, 2018, vol. 17, p.1892-1908
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting Tesa M Severson, Denise M. Wolf, Christina Yau, Justine K Peeters, Diederik Wehkam, Philip C Schouten, Suet-Feung Chin, Ian J Majewski, Magali Michaut, Astrid J Bosma, Bernard Pereira, Tycho Bismeijer, Lodewyk F A Wessels, Carlos Caldas, René Bernards, Iris M Simon, Annuska M. Glas, Sabine Linn, Laura J. Van't Veer
Breast Cancer Research, 2017, vol. 19
Equivalence of MammaPrint array types in clinical trials and diagnostics Inès Beumer, Anke Witteveen, Leonie Delahaye, Diederik Wehkamp, Mireille Snel, Christa Dreezen, John Zheng, Arno Floore, Guido Brink, Bob Chan, Sabine Linn, Rene Bernards, Laura van 't Veer, Annuska M. Glas
Breast Cancer Research and Treatment, 2016, vol. 156, p.279-287